{"entity":{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","aka":["ECHELON-3","Brentuximab vedotin with lenalidomide and rituximab in relapsed diffuse large B-cell lymphoma"],"tldr":"A phase 3 trial of Brentuximab vedotin, Rituximab, Lenalidomide in diffuse large b-cell lymphoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.","summary":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT04404283 by Seagen, a wholly owned subsidiary of Pfizer, with 239 participants enrolled, started 2020-08-20 and due to reach its primary completion in 2026-01-23. Interventions recorded: Brentuximab vedotin, Rituximab, Lenalidomide, Placebo. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04404283","url":"https://clinicaltrials.gov/study/NCT04404283"}],"tags":["ctgov-ingest"],"related":["lymphoma-roadmap","paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","polargo","starglo"],"cancers":["dlbcl"],"sections":[],"technologies":["adc","monoclonal-antibody","protac-degrader"],"targets":["cd30","cd20"],"drugs":["brentuximab-vedotin","rituximab","lenalidomide"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04404283","phase":"3","setting":"A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","result":"Median overall survival 13.8 against 8.5 months (hazard ratio 0.63, two-sided p = 0.009) and median progression-free survival 4.2 against 2.6 months (hazard ratio 0.53).","started":"2020-08-20","startedType":"actual","yearReported":2025,"enrolled":239,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04404283/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"paper":[{"id":"paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","kind":"paper","name":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","route":"/key-papers/paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025/"}],"trial":[{"id":"polargo","kind":"trial","name":"POLARGO","route":"/trials/polargo/"},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}